# üé® DESIGNER STRATEGIC RECOMMENDATION: Visual Asset Strategy

**From:** DESIGNER (using UI/UX & Product Design skill)  
**To:** LEAD  
**Date:** 2026-02-12 05:57 PST  
**Type:** Strategic Product Decision  
**Framework:** UI/UX & Product Design Advisory

---

## üìã **PROBLEM STATEMENT**

**One sentence:**  
We have created multiple visual assets (mockups, 3D molecules, components) without a clear strategy for which visuals serve which business objectives, where they should be placed, and what level of detail is appropriate for our current product stage.

---

## üéØ **CONSTRAINTS**

### **Time:**
- Protocol Builder Phase 1 is in progress (BUILDER's current focus)
- Mobile optimization completed (ButtonGroup responsive)
- No immediate deadline for additional mobile features

### **Budget:**
- No external design budget (in-house only)
- No budget for professional 3D rendering software
- Free/open-source tools only

### **Risk Tolerance:**
- **Clinical/Regulatory:** HIGH - Cannot use inaccurate molecular data in clinical interface
- **Reputational:** MEDIUM - Design quality reflects on platform credibility
- **Technical:** LOW - Can iterate on visual designs without breaking functionality

### **Team Capacity:**
- BUILDER: Focused on Protocol Builder implementation
- SOOP: Available for data provision
- DESIGNER: Available for design work
- LEAD: Strategic oversight
- INSPECTOR: QA/verification

### **Product Stage:**
- **MVP ‚Üí Pilot** transition
- Early adopter clinics testing
- Not yet at scale
- Focus on core functionality over polish

---

## ‚úÖ **ASSUMPTIONS THAT MUST BE TRUE**

1. **Clinicians are the primary users** (not patients, not admins)
2. **Mobile usage is significant** (>30% of sessions on mobile devices)
3. **Data accuracy is non-negotiable** (clinical research platform)
4. **Time-to-value matters** (clinicians need fast protocol logging)
5. **Visual credibility influences trust** (professional design = trustworthy platform)
6. **We will add more substances** (beyond the current 7)
7. **SOOP can provide accurate molecular data** (SMILES strings, binding data)

**Missing data to validate:**
- [ ] Actual mobile usage % (check analytics)
- [ ] User feedback on current visual design
- [ ] Clinician priorities (speed vs. features vs. visuals)

---

## üîÄ **OPTIONS ANALYSIS**

### **OPTION 1: Minimal Visuals (Speed-First)**

**Approach:**
- Use text-only substance names (no molecules)
- Keep current sidebar (no MobileSidebar)
- Mockups as reference only (no pixel-perfect specs)
- Focus 100% on Protocol Builder functionality

**Pros:**
- ‚úÖ Fastest time to market
- ‚úÖ Zero design debt
- ‚úÖ BUILDER can focus on core features
- ‚úÖ No risk of inaccurate visuals

**Cons:**
- ‚ùå Less engaging user experience
- ‚ùå Missed opportunity for differentiation
- ‚ùå May feel "unfinished" to users
- ‚ùå Harder to market/demo

**Failure modes:**
- Users perceive platform as "basic" or "unpolished"
- Harder to win competitive deals
- Lower user engagement/retention

**Best for:** Extremely tight timelines, technical-only users

---

### **OPTION 2: Strategic Visuals (Value-First)**

**Approach:**
- Use 2D molecular structures (accurate, simple)
- Implement MobileSidebar (better mobile UX)
- Create implementation specs for high-impact features only
- Prioritize visuals that drive core user goals

**Pros:**
- ‚úÖ Balanced speed + quality
- ‚úÖ Accurate molecular data (2D from SMILES)
- ‚úÖ Better mobile experience (thumb-optimized)
- ‚úÖ Professional appearance
- ‚úÖ Reversible decisions (can add 3D later)

**Cons:**
- ‚ö†Ô∏è Requires SOOP to provide SMILES strings
- ‚ö†Ô∏è 1-2 week delay for MobileSidebar implementation
- ‚ö†Ô∏è Some design work still needed

**Failure modes:**
- SOOP delays providing data
- MobileSidebar introduces bugs
- Over-engineering for MVP stage

**Best for:** MVP ‚Üí Pilot transition (our current stage)

---

### **OPTION 3: Premium Visuals (Differentiation-First)**

**Approach:**
- Interactive 3D molecule viewers (Three.js)
- Advanced data visualizations (heatmaps, 3D plots)
- Pixel-perfect mobile designs
- Full Clinical Intelligence Platform

**Pros:**
- ‚úÖ Maximum differentiation
- ‚úÖ "Wow factor" in demos
- ‚úÖ Future-proof architecture
- ‚úÖ Competitive advantage

**Cons:**
- ‚ùå 4-6 week implementation time
- ‚ùå High complexity (3D rendering, performance)
- ‚ùå Requires extensive data from SOOP
- ‚ùå May distract from core functionality
- ‚ùå Over-engineered for current stage

**Failure modes:**
- Delays Protocol Builder launch
- Performance issues on mobile
- Users don't value advanced visuals
- Technical debt from complex visualizations

**Best for:** Post-launch, funded growth stage

---

## üéØ **RECOMMENDATION: OPTION 2 (Strategic Visuals)**

### **The Decision:**
Implement **strategic, high-value visuals** that support core user goals without delaying Protocol Builder launch.

### **Rationale:**

1. **Product Stage Alignment:**
   - We're in MVP ‚Üí Pilot transition
   - Need professional appearance to win early adopters
   - But can't afford 4-6 week delays for "nice-to-haves"

2. **User Value:**
   - 2D molecular structures provide educational value (accurate)
   - MobileSidebar improves mobile UX (30%+ of users)
   - Both are **reversible** decisions (can enhance later)

3. **Risk Mitigation:**
   - 2D structures are scientifically accurate (no clinical risk)
   - MobileSidebar is isolated component (low technical risk)
   - Can implement incrementally (no big-bang release)

4. **Competitive Position:**
   - Professional visuals differentiate from spreadsheet-based competitors
   - Not over-engineered (avoid "vaporware" perception)
   - Demonstrates technical capability without distraction

---

## ‚ö†Ô∏è **RISKS & MITIGATIONS**

### **Risk 1: SOOP delays providing SMILES strings**
**Likelihood:** MEDIUM  
**Impact:** MEDIUM  
**Mitigation:**
- Use molecular formulas only as fallback (C‚ÇÅ‚ÇÇH‚ÇÅ‚ÇáN‚ÇÇO‚ÇÑP)
- Implement 2D structures in Phase 2 if delayed
- Don't block other work on this dependency

### **Risk 2: MobileSidebar introduces bugs**
**Likelihood:** LOW  
**Impact:** MEDIUM  
**Mitigation:**
- Keep existing Sidebar.tsx as fallback
- Feature flag MobileSidebar (easy rollback)
- INSPECTOR tests thoroughly before release

### **Risk 3: Users don't value molecular visuals**
**Likelihood:** LOW  
**Impact:** LOW  
**Mitigation:**
- Collect user feedback in pilot
- A/B test with/without visuals
- Easy to remove if not valued

### **Risk 4: Design work delays Protocol Builder**
**Likelihood:** LOW  
**Impact:** HIGH  
**Mitigation:**
- DESIGNER works in parallel (not blocking BUILDER)
- Implementation specs created only for approved features
- BUILDER prioritizes Protocol Builder over visuals

---

## üìä **METRICS & INSTRUMENTATION**

### **Success Metrics:**
1. **User Engagement:**
   - Time on substance detail pages (baseline: 0s ‚Üí target: 30s+)
   - Click-through rate on molecular structures (target: >20%)

2. **Mobile Experience:**
   - Mobile bounce rate (target: <40%)
   - Mobile session duration (target: >3 min)
   - Mobile navigation ease (qualitative feedback)

3. **Perception:**
   - User feedback on "professional appearance" (target: >80% positive)
   - Demo conversion rate (baseline TBD)

### **Instrumentation Needed:**
- [ ] Add analytics to substance detail pages
- [ ] Track mobile vs desktop usage
- [ ] Collect user feedback survey (post-pilot)

---

## üöÄ **NEXT ACTIONS (Priority Order)**

### **Immediate (This Week):**

1. **LEAD approves** this strategic direction  
   **Owner:** LEAD  
   **Done when:** Approval documented in decision log

2. **SOOP provides** SMILES strings for 7 substances  
   **Owner:** SOOP  
   **Done when:** Data added to `ref_substance_properties` table  
   **Acceptance criteria:** Valid SMILES strings, verified against PubChem

3. **DESIGNER creates** 2D molecular structure component spec  
   **Owner:** DESIGNER  
   **Done when:** Implementation spec document created  
   **Acceptance criteria:** Clear component API, styling guidelines, data requirements

### **Short-term (Next Week):**

4. **BUILDER implements** 2D molecular structures (if approved)  
   **Owner:** BUILDER  
   **Done when:** Structures display on substance cards  
   **Acceptance criteria:** Accurate rendering, mobile-responsive, <1s load time

5. **BUILDER implements** MobileSidebar (if approved)  
   **Owner:** BUILDER  
   **Done when:** Feature-flagged, tested on mobile  
   **Acceptance criteria:** No regressions, thumb-optimized, <300ms animation

6. **INSPECTOR verifies** mobile implementations  
   **Owner:** INSPECTOR  
   **Done when:** QA checklist completed  
   **Acceptance criteria:** No critical bugs, accessibility compliant

### **Long-term (Month 1):**

7. **DESIGNER evaluates** user feedback on visuals  
   **Owner:** DESIGNER  
   **Done when:** Feedback analysis report created  
   **Acceptance criteria:** Quantitative + qualitative data, recommendations for Phase 2

---

## üîç **STRESS-TEST QUESTIONS**

### **Question 1: User Value**
**"What happens if we ship Protocol Builder with zero visual enhancements?"**
- **Answer:** Functionality works, but platform may feel "unfinished"
- **Evidence needed:** User feedback from current pilot users
- **Decision impact:** If users don't care about visuals, skip them entirely

### **Question 2: Competitive Position**
**"Do our competitors have molecular visualizations?"**
- **Answer:** Unknown - need competitive analysis
- **Evidence needed:** Screenshots of competitor platforms
- **Decision impact:** If competitors have 3D viewers, we may need to match

### **Question 3: Mobile Usage**
**"What % of our users are actually on mobile?"**
- **Answer:** Assumed >30%, but not verified
- **Evidence needed:** Analytics data from current users
- **Decision impact:** If <10% mobile, MobileSidebar is low priority

### **Question 4: Data Availability**
**"Can SOOP realistically provide SMILES strings this week?"**
- **Answer:** Assumed yes, but not confirmed
- **Evidence needed:** SOOP's confirmation + timeline
- **Decision impact:** If delayed, use formulas-only as fallback

### **Question 5: Implementation Complexity**
**"How long will MobileSidebar actually take to implement and test?"**
- **Answer:** Estimated 2-3 days, but not validated
- **Evidence needed:** BUILDER's estimate
- **Decision impact:** If >1 week, defer to Phase 2

---

## üìù **DECISION LOG ENTRY**

**Date:** 2026-02-12  
**Decision:** Implement strategic visuals (2D molecules + MobileSidebar)  
**Owner:** LEAD  
**Rationale:** Balances professional appearance with MVP speed  
**Alternatives considered:** Minimal visuals, Premium visuals  
**Key risks:** SOOP data delay, MobileSidebar bugs, user indifference  
**Mitigations:** Fallbacks, feature flags, user feedback collection  
**Metrics to monitor:** Engagement, mobile UX, user perception  
**Review date:** 2026-02-26 (2 weeks post-implementation)

---

## ‚úÖ **QUALITY CHECKLIST**

- [x] Problem statement is one sentence
- [x] Constraints are explicit (time, budget, risk, team)
- [x] Assumptions are testable
- [x] Options have pros, cons, and failure modes
- [x] Recommendation has clear rationale
- [x] Risks have mitigations
- [x] Metrics are specific and measurable
- [x] Next actions have owners and acceptance criteria
- [x] Stress-test questions challenge assumptions
- [x] Aligns to product stage (MVP ‚Üí Pilot)

---

## üéØ **WHAT EVIDENCE WOULD CHANGE THIS RECOMMENDATION?**

**I would recommend OPTION 1 (Minimal Visuals) if:**
- Mobile usage is <10% of total sessions
- Users explicitly request "faster, simpler" over "prettier"
- Protocol Builder launch is delayed by >2 weeks

**I would recommend OPTION 3 (Premium Visuals) if:**
- We secure funding for dedicated design/dev resources
- Competitors launch with 3D molecular viewers
- User feedback shows strong demand for advanced visualizations
- We move to growth stage (post-pilot)

---

**Strategic Recommendation Submitted:** 2026-02-12 05:57 PST  
**Framework Used:** UI/UX & Product Design skill  
**Confidence Level:** HIGH (based on product stage alignment)  
**Awaiting:** LEAD's approval to proceed with Option 2
